NCT07028632View on ClinicalTrials.gov

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Parkinson Disease (PD)
Interventions
BIOLOGICAL

Human Dopaminergic Progenitor Cells

Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.

Trial Locations (1)

100730

Beijing Hospital, Beijing

All Listed Sponsors
lead

iRegene Therapeutics Co., Ltd.

INDUSTRY